Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs

Morgan Stanley forecasts the obesity-drug market will reach $190 billion by 2035, more than double its 2025 level, with growth supported by oral treatments, broader Medicare coverage and potential expansion in international markets. The article argues that GLP-1 drugs could gain additional uses in cardiovascular, kidney, liver, arthritis and sleep-apnea conditions; an NIH-funded mouse study also found semaglutide improved measures of function and aging, but human anti-aging effects remain unproven. It highlights Novo Nordisk and Eli Lilly, as well as Pfizer and Merck as companies with GLP-1 drugs in development.

Analysis

The investable signal is not the mouse-aging result; it is whether broader indications and easier-to-use formulations convert into durable, reimbursed patient volume. Near term, that makes LLY and NVO the clearest commercial beneficiaries, but also leaves them exposed to a high bar: oral uptake, supply execution, persistence, and net pricing must validate the growth narrative. Broader coverage can expand the addressable market while simultaneously strengthening payer leverage over price.

The article’s long-range market estimate and speculative human-use extrapolation risk encouraging investors to capitalize distant revenue too aggressively. The mouse study is not evidence of human longevity benefit, and belief-driven demand is not equivalent to reimbursed demand. International opportunity is similarly conditional on affordability, local access, and safety evidence—not simply population size.

Over 1–3 months, monitor company disclosures on oral-product uptake, capacity, access, and realized pricing; these are nearer-term valuation catalysts than additional preclinical findings. Over 6–18 months, successful outcomes evidence in established comorbidities could support broader coverage and reduce dependence on weight-loss demand. Conversely, weaker persistence, adverse safety signals, constrained supply, or payer restrictions would impair the volume thesis. PFE and MRK are potential pipeline optionality, not equivalent current beneficiaries; absent program-specific clinical and commercial evidence, assigning them GLP-1 economics is premature.

Key Decisions for Investors

• Prefer a staged, diversified exposure to LLY and NVO over buying the entire long-duration growth narrative at once. Add only as earnings and guidance confirm volume growth without material deterioration in net pricing; this is a multi-quarter thesis, not a trade on the mouse study.
• Treat oral uptake, production capacity, treatment persistence, and payer access as the next-quarter-to-year monitoring set. If growth depends on price concessions or access does not broaden, reduce exposure even if headline prescription demand remains strong.
• Do not buy PFE or MRK as GLP-1 proxies on pipeline mentions alone. Revisit only after program-specific clinical data, development timelines, and evidence of a viable route to market; until then their GLP-1 contribution is an alert, not an earnings thesis.
• Falsifiers: guidance or reported demand weakens, net pricing deteriorates, supply fails to meet demand, safety findings constrain use, or clinical evidence does not support broader indications. Human anti-aging benefit remains unproven and should not be included in base-case valuation.